BR100 Increased By (1.02%)
BR30 Increased By (1.68%)
KSE100 Increased By (0.98%)
KSE30 Increased By (1.06%)
AGHA 7.69 Increased By ▲ 0.23 (3.08%)
BECO 5.31 Increased By ▲ 0.04 (0.76%)
BML 61.23 Increased By ▲ 3.97 (6.93%)
BOP 36.00 Increased By ▲ 1.25 (3.6%)
CNERGY 11.25 Increased By ▲ 0.19 (1.72%)
CSIL 6.17 Increased By ▲ 0.34 (5.83%)
FCCL 56.88 Increased By ▲ 0.46 (0.82%)
FFL 16.51 Increased By ▲ 0.10 (0.61%)
FNEL 1.20 No Change ▼ 0.00 (0%)
KEL 7.42 Increased By ▲ 0.10 (1.37%)
KOSM 6.05 Decreased By ▼ -0.10 (-1.63%)
LOTCHEM 27.20 Increased By ▲ 0.08 (0.29%)
MLCF 103.09 Increased By ▲ 5.15 (5.26%)
NBP 207.63 Increased By ▲ 0.75 (0.36%)
NCPL 61.92 Increased By ▲ 5.50 (9.75%)
NPL 72.18 Increased By ▲ 6.41 (9.75%)
OGDC 318.49 Increased By ▲ 2.19 (0.69%)
PACE 11.06 Increased By ▲ 0.19 (1.75%)
PAEL 44.38 Increased By ▲ 2.08 (4.92%)
PIBTL 16.90 Increased By ▲ 0.12 (0.72%)
PPL 222.48 Increased By ▲ 1.79 (0.81%)
PRL 63.81 Increased By ▲ 0.16 (0.25%)
PTC 73.16 Increased By ▲ 1.34 (1.87%)
SSGC 27.25 Increased By ▲ 0.17 (0.63%)
TBL 9.88 Increased By ▲ 0.16 (1.65%)
TELE 8.81 Increased By ▲ 0.08 (0.92%)
TPL 20.34 Increased By ▲ 0.94 (4.85%)
TPLP 14.97 Increased By ▲ 0.19 (1.29%)
TREET 24.10 Increased By ▲ 0.70 (2.99%)
TRG 62.37 Increased By ▲ 0.96 (1.56%)
Markets

Bayer to cut more than 1.5bn euros in costs

  • The cash flow freed up would be allocated for investments in further innovation, profitable growth opportunities and debt reduction.
  • Bayer said it expects 2021 sales to be about the same as in 2020, despite significant headwinds from COVID-19.
Published Updated
By

BERLIN: German drugs company Bayer AG announced plans on Wednesday for more than 1.5 billion euros ($1.76 billion)of cost cuts as of 2024, on top of savings announced in 2018, as it battles with a slowdown in the agricultural market.

The cash flow freed up would be allocated for investments in further innovation, profitable growth opportunities and debt reduction. It said the restructuring, which may also lead to extra job cuts, is in the early stages of planning.

Bayer said it expects 2021 sales to be about the same as in 2020, despite significant headwinds from COVID-19, especially in the agricultural market, and said it expects core earnings per share to be slightly lower at constant exchange rates.

Comments

Comments are closed for this article.